arrow
Back
I

Ian E. Krop

memorial sloan kettering cancer center

99H-index
859Paper Count
4.2WCitation Count
Published Papers 216
Publication Date
Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results
err2026-03-18
err0
errOAAI
errRashmi K. Murthy; Barbara J. O’Brien; Donald A. Berry; Akshara Singareeka-Raghavendra; Maria Gule Monroe; Jason Johnson; Jason White; Jill Schwartz-Gomez; Ariel Topletz-Erickson; Mina Lobbous; Kristen Riley; Michelle Melisko; Aki Morikawa; Sherise D. Ferguson; John F. de Groot; Ian E. Krop; Vicente Valero; Mothaffar F. Rimawi; Antonio C. Wolff; Debu Tripathy; Nancy U. Lin; Erica M. Stringer-Reasor
errShare
errSave
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial
err2025-11-28
err0
errOAAI
errAdrienne G. Waks; Jingxin Fu; Xiangying Chu; Busem Binboga Kurt; Tianyu Li; Thomas M. Kuntz; Yizhuo Shen; David Yang; Kevin Meli; Brendan Reardon; Jihye Park; Ann Partridge; Daniel Abravanel; Rinath Jeselsohn; Eileen Wrabel; Jillian Alberti; Molly DiLullo; Serenity Chen; Ayesha Mohammed-Abreu; Xiaopeng Sun; Justin M. Balko; Miranda Kleijn; William Audeh; Xochitl C. Morgan; Ian E. Krop; Nabihah Tayob; Eliezer M. Van Allen; Elizabeth A. Mittendorf; Sara M. Tolaney
errShare
errSave
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
err2025-11-18
err0
PREAI
errC. Saura; J. Cortés; S. Modi; S.-B. Kim; E. Hamilton; S.A. Hurvitz; I.E. Krop; G. Curigliano; H. Iwata; S.-A. Im; P. Herbolsheimer; M. Karnoub; A. Boran; Y. Kuwahara; A. Egorov; F. André
errShare
errSave
Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)
err2025-11-01
err0
PREAI
errNader-Marta, Guilherme; Chu, Xiangying; Mukhopadhyay, Satabhisa; Abramson, Vandana G.; Brufsky, Adam; Stringer-Reasor, Erica Michelle; Dent, Susan Faye; Traina, Tiffany A.; Carey, Lisa A.; Rimawi, Mothaffar F.; Specht, Jennifer M.; Miller, Kathy D.; Santa-Maria, Cesar Augusto; Dasgupta, Tathagata; Kurt, Busem Binboga; Demeo, Michelle; Krop, Ian E.; Tung, Nadine M.; Schnitt, Stuart J.; Tayob, Nabihah; Mayer, Erica L.
errShare
errSave
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA
err2025-09-09
err0
errOAAI
errHeather A. Parsons; Conor Messer; Katheryn Santos; Jakob Weiss; David Merrell; Brian P. Danysh; Melissa E. Hughes; Gregory J. Kirkner; Ashka Patel; Julian Hess; Kerry Sendrick; Chip Stewart; Elizabeth Grant; Kristy Schlueter-Kuck; Albert Grinshpun; Nikhil Wagle; Jamunarani Veeraraghavan; Jose Pablo Leone; Rachel A. Freedman; Otto Metzger; Rachel Schiff; Eric P. Winer; Sara M. Tolaney; Mothaffar Rimawi; Ian E. Krop; Gad Getz; Nancy U. Lin
errShare
errSave
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients
err2025-09-01
err3
errOAAI
errLambertini, Matteo; Allegranza, Deirdre; Laubender, Ruediger P.; Harbeck, Nadia; Swain, Sandra M.; Geyer, Charles E.; Slamon, Dennis J.; Bobba, Gabriella; Lambertini, Chiara; de Haas, Sanne; Restuccia, Eleonora; Vaz-Luis, Ines; Cameron, David A.; Krop, Ian E.; Winer, Eric P.; Anderson, Richard A.
errShare
errSave
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
err2025-09-01
err2
PREAI
errTarantino, Paolo; Lee, Do; Foldi, Julia; Soulos, Pamela R.; Gross, Cary P.; O'Meara, Tess; Grinda, Thomas; Morganti, Stefania; Waks, Adrienne G.; Winer, Eric P.; Lin, Nancy U.; Krop, Ian E.; Tolaney, Sara M.; Sammons, Sarah; Lustberg, Maryam
errShare
errSave
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
err2025-08-05
err0
errOAAI
errH.S. Rugo; E. Tokunaga; H. Iwata; V. Petry; E.F. Smit; Y. Goto; D.-W. Kim; K. Shitara; J.F. Gruden; S. Modi; J. Cortés; I. Krop; P.A. Jänne; Y. Cheng; C. Taitt; F.-C. Cheng; C.A. Powell
errShare
errSave
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)
err2025-07-01
err0
PREAI
errV. Gambardella; M.K. Accordino; P.L. Bedard; A. Cervantes; E. Hamilton; A. Italiano; K. Kalinsky; I.E. Krop; M. Oliveira; C. Saura; P. Schmid; N.C. Turner; A. Varga; A. Fernandez-Saranillo; Y. Jin; S. Royer-Joo; U. Peters; N. Shankar; J.L. Schutzman; D. Juric; K.L. Jhaveri
errShare
errSave
Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer
err2025-07-01
err0
PREAI
errP. Tarantino; D. Lee; J. Foldi; P.R. Soulos; C.P. Gross; T. Grinda; E.P. Winer; N.U. Lin; I.E. Krop; S.M. Tolaney; M. Lustberg; S. Sammons
errShare
errSave
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
errBREAST
IF7.9
err2025-06-01
err0
errOAAI
errHennessy, Maeve A.; Cimino-Mathews, Ashley; Carter, Jodi M.; Kachergus, Jennifer M.; Ma, Yaohua; Leal, Jeffrey P.; Solnes, Lilja B.; Abramson, Vandana G.; Carey, Lisa A.; Rimawi, Mothaffar; Specht, Jennifer; Storniolo, Anna Maria; Vaklavas, Christos; Krop, Ian; Winer, Eric; Denbow, Rita; Valero, Vincente; Wolff, Antonio C.; Wahl, Richard L.; Huang, Chiung-Yu; Stearns, Vered; Thompson, E. Aubrey; Connolly, Roisin M.
errShare
errSave
A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer
err2025-05-16
err0
PREAI
errStefania Morganti; Xiangying Chu; Tarah J. Ballinger; Nisha Unni; Sarah Sinclair; Robert Wesolowski; Alyssa M. Pereslete; Paulina Lange; Nabihah Tayob; Nancy U. Lin; Jose P. Leone; Ian E. Krop; Sara M. Tolaney; Heather A. Parsons
errShare
errSave
Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium
err2025-04-08
err0
PREAI
errKomal Jhaveri; Carey K. Anders; Aditya Bardia; Manali Bhave; A. Jo Chien; Ian Krop; Tiffany A. Traina; Yara Abdou; Reva Basho; Alison K. Conlin; Francisco J. Esteva; Kevin R. Fox; Vijayakrishna Gadi; Peter A. Kaufman; Anya Litvak; Cynthia X. Ma; Eleftherios P. Mamounas; Heather McArthur; Kelly McCann; Zahi Mitri; Rebecca Shatsky; Melinda Telli; Mylin A. Torres; Kevin Kalinsky
errShare
errSave
PIK3CAH1047R- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling (vol 35, pg 2961, 2015)
err2025-01-31
err0
PREAI
errCheng, H.; Liu, P.; Ohlson, C.; Xu, E.; Symonds, L.; Isabella, A.; Mueller, W. J.; Lin, N. U.; Krop, I. E.; Roberts, T. M.; Winer, E. P.; Arteaga, C. L.; Zhao, J. J.
errShare
errSave
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
err2024-12-01
err2
errOAAI
errAndre, F.; Cortes, J.; Curigliano, G.; Modi, S.; Li, W.; Park, Y. H.; Chung, W. -p.; Kim, S. -b.; Yamashita, T.; Pedrini, J. L.; Im, S. -a.; Tseng, L. -m.; Harbeck, N.; Krop, I.; Nakatani, S.; Tecson, K.; Ashfaque, S.; Egorov, A.; Hurvitz, S. A.
errShare
errSave
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2 D breast cancer
err2024-06-01
err1
errOAAI
errGrinshpun, A.; Ren, S.; Graham, N.; Demeo, M. K.; Wrabel, E.; Carter, J.; Tayob, N.; Pereslete, A.; Hamilton, E.; Juric, D.; Mayer, E. L.; Tolaney, S. M.; Krop, I. E.; Metzger, O.
errShare
errSave
Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive Breast Cancer
err2024-05-02
err0
PREAI
errMetzger, Otto; Kim, Se Eun; Tayob, Nabihah; Viale, Giuseppe; Yardley, Denise; Prat, Aleix; Abramson, Vandana; Spring, Laura; Waks, Adrienne; Wrabel, Eileen; Demeo, Michelle; Bardia, Aditya; Dell'Orto, Patrizia; Russo, Leila; King, Tari; Michor, Franziska; Winer, Eric; Polyak, Kornelia; Tolaney, Sara; Krop, Ian
errShare
errSave
A011801 (CompassHER2 RD): Postneoadjuvant T-DM1+tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
err2024-05-02
err0
PREAI
errO'Sullivan, Ciara; Ballman, Karla; McCall, Linda; Zemla, Tyler; Weiss, Anna; Mitchell, Melissa; Blinder, Victoria; Tung, Nadine; Irvin, William; Lee, Myounghee; Kamaraju, Sailaja; Goetz, Matthew; Symmans, W. Fraser; Borges, Virginia; Krop, Ian; Partridge, Ann; Carey, Lisa
errShare
errSave
AVIATOR/ TBCRC045: A randomized phase II study of vinorelbine (N) plus trastuzumab (H) alone or combined with avelumab (A) plus /- utomilumab (U) in patients (pts) with HER2+metastatic breast cancer (MBC) (NCT03414658)
err2024-05-02
err0
PREAI
errWaks, Adrienne; Shi, Ruichao; Regan, Meredith; Dang, Chau; Santa-Maria, Cesar; Westbrook, Kelly; Abramson, Vandana; Murthy, Rashmi; Nanda, Rita; Rugo, Hope; Clark, Amy; Mainor, Candace; Dees, Claire; Hoyos, Valentina; Miller, Kathy; Stringer-Reasor, Erica; Hunter, Natasha; Oh, Sun Young; Demeo, Michelle; Okpoebo, Amanda; Elias, Erin; Kurt, Busem; Lin, Nancy; Rimawi, Mothaffar; Wolff, Antonio; Mittendorf, Elizabeth; Goel, Shom; Tolaney, Sara; Loi, Sherene; Krop, Ian
errShare
errSave
Anti-Mullerian hormone in Young women with breast CAncer to predict permanent loss of ovarian function after chemotherapy and anti-HER2 therapy (AMYCA): a biomarker analysis of the BETH and KAITLIN trials
err2024-05-02
err0
PREAI
errLambertini, Matteo; Allegranza, Deirdre; Laubender, Ruediger; Harbeck, Nadia; Swain, Sandra; Geyer, Charles; Slamon, Dennis; Bobba, Gabriella; Lambertini, Chiara; De Haas, Sanne Lysbet; Restuccia, Eleonora; Luis, Ines Vaz; Cameron, David; Krop, Ian; Winer, Eric; Anderson, Richard
errShare
errSave